


Please type a plus sign (+) inside this box → ☐



PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known		
				Application Number	08/630,383	
				Filing Date	April 10, 1996	
				First Named Inventor	Pouletty et al.	
				Group Art Unit	1644	
				Examiner Name	Schwadron, R.	
Attorney Docket Number	A-55320-2/DJB/TAF/PTO CENTER 1600/2900					
Sheet	1	of	1			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
PB3	1	Benjamin et al., "Induction of tolerance by monoclonal antibody therapy," Nature, 320: 449-451 (April 1986).		
	2	Galili et al., "A unique natural human IgG antibody with anti- α -galactosyl specificity," J. Exp. Med., 60: 1519-1531 (November 1984).		
	3	Galili, U.S.S.N. "Interaction of the natural anti-Gal antibody with α -galactosyl epitopes: a major obstacle for xenotransplantation in humans," Immunology Today, 14(10): 480-482 (1993).		
	4	Hall et al., "In vitro efficacy of transferrin-toxin conjugates against glioblastoma multiforme," J. Neurosurg., 76: 838-844 (1992).		
	5	Hoshino et al., "In vitro cytotoxicities and in vivo distribution of transferrin-Platinum (II)," Journal of Pharmaceutical Sciences, 84(2): 216-221 (February 1995).		
	6	Krantz et al., "Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis," Proc. Natl. Acad. Sci. USA, 92: 9057-9061 (September 1995).		
	7	Renner et al., "Tumor therapy by immune recruitment with bispecific antibodies," Immunological Reviews, 145: 179-209 (1995).		
	8	Sato et al., "Enhancement of anti-tumor activity of recombinant interleukin-2 (rIL-2) by immunocomplexing with a monoclonal antibody against rIL-2," Biotherapy, 6: 225-231 (1993).		
	9	Soulillou, J.P. "Biological Reagents for Immunosuppressants," Transplant Proc., 27(1): 106-108 (February 1995).		
	10	Strom et al., Genetically Engineered Proteins for Immunoregulation," Transplantation Proceedings, 27(5): 18-20 (October 1995).		
	11	van Ravenswaay et al., "Analysis of production, purification, and cytolytic potential of bi-specific antibodies reactive with ovarian-carcinoma-associated antigens and the T-cell antigen CD3," Int. J. Cancer, 55: 128-136 (1993).		
	12	Lussow et al., "Targeting of activated t-cells with natural cytotoxic antibodies via an H-2-hapten conjugate prolongs graft survival," Transplantation Proceedings, 28(2): 571-572 (April 1996).		
	13	Lussow et al., "Redirecting Circulating Antibodies via Ligand Hapten Conjugates Eliminates Target Cells In Vivo," Journal of Immunotherapy, 19(4): 257-265 (1996).		
	14	Lussow et al., "Targeting of Antihapten Antibodies to Activated T-Cells via an H-2-Hapten Conjugate Prolongs Cardiac Graft Survival," Transplantation, 62(12): 1703-1708 (1996).		

Examiner Signature		Date Considered	10/7/2001
--------------------	--	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.